Idorsia’s Clazosentan Fails Yet Another Pivotal Brain Injury Trial As Cash Runway Dwindles

 
• By Ayisha Sharma

Funding pressures grow as the Swiss firm’s endothelin A receptor antagonist clazosentan once again misses the mark in a Phase III brain injury trial aimed at breaking into the Western market, despite prior success in similar Japanese trials.  

Dark tunnel with a road winding through to a light at the end
It's Unclear Whether There's A Light At The End Of The Tunnel • Source: Shutterstock

More from Clinical Trials

More from R&D